Literature DB >> 29335868

Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging.

Seo-Youn Choi1, Young Kon Kim2, Ji Hye Min3, Tae Wook Kang4, Woo Kyoung Jeong4, Soohyun Ahn5, Hojeong Won5.   

Abstract

OBJECTIVES: To determine ancillary features that help distinguish between scirrhous hepatocellular carcinoma (S-HCC) and intrahepatic cholangiocarcinoma (ICC) and investigate added value of ancillary features to enhancement pattern-based diagnosis on gadoxetic acid-enhanced MRI.
METHODS: This retrospective study included 96 patients with S-HCCs and 120 patients with ICCs who underwent gadoxetic acid MRI before surgical resection. Two observers reviewed MRIs of the tumours. After determining ancillary features for differentiating tumour types, we measured the diagnostic performance of adding ancillary features to enhancement pattern-based diagnosis.
RESULTS: T2 central darkness, capsule and septum were significant and independent features differentiating S-HCC from ICC (p ≤ .06). Adding ancillary features to enhancement pattern led to increased accuracy (observer 1, 78.9 vs. 93.8 %; observer 2, 80.3 vs. 92.8 %; p < .001), sensitivity (observer 1, 74.5 vs. 96.4 %; observer 2, 77.1 vs. 93.2 %; p < .001 and .001), and specificity (observer 1, 82.5 vs. 91.7 %; observer 2, 82.9 vs. 92.5 %; p = .006 and .005) for diagnosis of S-HCC by differentiation from ICC.
CONCLUSIONS: Adding ancillary features capsule, septum and T2 central darkness to conventional enhancement patterns on gadoxetic acid-enhanced MRI improved accuracy, sensitivity and specificity for S-HCC diagnosis with differentiation from ICC. KEY POINTS: • Capsule, septum, and T2 central darkness were ancillary features for S-HCC. • A typical HCC enhancement was seen in 31.3% of S-HCCs. • Ancillary MRI features were useful in differentiation between S-HCC and ICC.

Entities:  

Keywords:  Bile duct neoplasm; Carcinoma, hepatocellular; Cholangiocarcinoma; Liver neoplasms; Magnetic resonance imaging

Mesh:

Substances:

Year:  2018        PMID: 29335868     DOI: 10.1007/s00330-017-5196-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  32 in total

1.  Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.

Authors:  Y S Chong; Y K Kim; M W Lee; S H Kim; W J Lee; H C Rhim; S J Lee
Journal:  Clin Radiol       Date:  2012-03-15       Impact factor: 2.350

2.  Clinicopathological study of scirrhous hepatocellular carcinoma.

Authors:  Mina Kurogi; Osamu Nakashima; Hisamitsu Miyaaki; Masaru Fujimoto; Masamichi Kojiro
Journal:  J Gastroenterol Hepatol       Date:  2006-09       Impact factor: 4.029

3.  Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee; Sang Min Lee; Jeong Sub Lee; Jin Young Park; Joon Koo Han
Journal:  J Magn Reson Imaging       Date:  2016-04-18       Impact factor: 4.813

4.  Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: Classification tree analysis applying capsule and septum.

Authors:  Ji Hye Min; Young Kon Kim; Seo-Youn Choi; Woo Kyoung Jeong; Won Jae Lee; Sang Yun Ha; Soohyun Ahn; Hyeon Seon Ahn
Journal:  Eur J Radiol       Date:  2017-04-13       Impact factor: 3.528

5.  Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation.

Authors:  Hyeon Tae Jeong; Myeong-Jin Kim; Yong Eun Chung; Jin Young Choi; Young Nyun Park; Ki Whang Kim
Journal:  AJR Am J Roentgenol       Date:  2013-10       Impact factor: 3.959

6.  MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation.

Authors:  Y Maetani; K Itoh; C Watanabe; T Shibata; F Ametani; H Yamabe; J Konishi
Journal:  AJR Am J Roentgenol       Date:  2001-06       Impact factor: 3.959

7.  Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?

Authors:  Ijin Joo; Jeong Min Lee; Dong Ho Lee; Ju Hyeon Jeon; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2015-03-14       Impact factor: 5.315

8.  Gadoxetic acid disodium-enhanced MR imaging of cholangiolocellular carcinoma of the liver: imaging characteristics and histopathological correlations.

Authors:  Hiroki Haradome; Toshiyuki Unno; Hiroyuki Morisaka; Yusuke Toda; Thomas C Kwee; Hiroshi Kondo; Keiji Sano; Tomoaki Ichikawa; Fukuo Kondo; Masahiko Sugitani; Tadatoshi Takayama
Journal:  Eur Radiol       Date:  2017-04-24       Impact factor: 5.315

9.  The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.

Authors:  Tae Yeon Jeon; Seong Hyun Kim; Won Jae Lee; Hyo K Lim
Journal:  Abdom Imaging       Date:  2009-04-07

10.  Clinicopathological study of hepatocellular carcinoma with peliotic change.

Authors:  Masaru Fujimoto; Osamu Nakashima; Mina Komuta; Toshimitsu Miyaaki; Masamichi Kojiro; Hirohisa Yano
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

View more
  10 in total

1.  Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.

Authors:  Shoji Kubo; Hiroji Shinkawa; Yoshinari Asaoka; Tatsuya Ioka; Hiroshi Igaki; Namiki Izumi; Takao Itoi; Michiaki Unno; Masayuki Ohtsuka; Takuji Okusaka; Masumi Kadoya; Masatoshi Kudo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Yoshihiro Sakamoto; Hideyuki Sakurai; Tadatoshi Takayama; Osamu Nakashima; Yasushi Nagata; Etsuro Hatano; Kenichi Harada; Takamichi Murakami; Masakazu Yamamoto
Journal:  Liver Cancer       Date:  2022-02-23       Impact factor: 12.430

2.  Diagnostic Performance of LI-RADS Version 2018 for Primary Liver Cancer in Patients With Liver Cirrhosis on Enhanced MRI.

Authors:  Xinai Liu; Xiaoyan Ni; Yubo Li; Chun Yang; Yi Wang; Chunzheng Ma; Changwu Zhou; Xin Lu
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

Review 3.  MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification.

Authors:  Ja Kyung Yoon; Jin-Young Choi; Hyungjin Rhee; Young Nyun Park
Journal:  Eur Radiol       Date:  2022-03-08       Impact factor: 7.034

4.  Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.

Authors:  Xin Zhang; Wen-Juan Huang; Meng-Lin Zhang; Wen Wang; Ye Niu; Rui-Tao Wang; Zeng-Yao Liu
Journal:  BMC Gastroenterol       Date:  2022-06-06       Impact factor: 2.847

5.  Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.

Authors:  Tyler J Fraum; Roberto Cannella; Daniel R Ludwig; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Eur Radiol       Date:  2019-10-25       Impact factor: 5.315

Review 6.  Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging.

Authors:  Jae Hyun Kim; Ijin Joo; Jeong Min Lee
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

7.  Scirrhous Hepatocellular Carcinoma: Systematic Review and Pooled Data Analysis of Clinical, Radiological, and Histopathological Features.

Authors:  Anastasia Murtha-Lemekhova; Juri Fuchs; Erik Schulz; Anthe Suzan Sterkenburg; Philipp Mayer; Jan Pfeiffenberger; Katrin Hoffmann
Journal:  J Hepatocell Carcinoma       Date:  2021-10-22

Review 8.  Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI.

Authors:  Jelena Djokic Kovač; Aleksandra Janković; Aleksandra Đikić-Rom; Nikica Grubor; Andrija Antić; Vladimir Dugalić
Journal:  Curr Oncol       Date:  2022-01-30       Impact factor: 3.677

9.  Non-invasive diagnosis strategy of hepatocellular carcinoma in low-risk population.

Authors:  Zonglin Xie; Zhenpeng Peng; Yujian Zou; Han Xiao; Bin Li; Qian Zhou; Shuling Chen; Lixia Xu; Jingxian Shen; Yunxian Mo; Sui Peng; Ming Kuang; Jianting Long; Shi-Ting Feng
Journal:  BMC Cancer       Date:  2022-06-28       Impact factor: 4.638

Review 10.  Pearls and pitfalls in magnetic resonance imaging of hepatocellular carcinoma.

Authors:  Jelena Djokic Kovac; Tamara Milovanovic; Vladimir Dugalic; Igor Dumic
Journal:  World J Gastroenterol       Date:  2020-05-07       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.